USA As Represented by Secretary of the Navy

Keith Limbach

Joseph T Bruder

C Richter King

Denise Louise Doolan

Martha Sedegah

Douglas E Brough

Imre Kovesdi

Duncan L McVey

Thomas L Richie

Daniel John Carucci

Joao Carlos Aguair

Walter R Weiss

Joao Aguiar

The invention provides novel malaria polypeptides expressed at the pre-erythrocytic stage of the malaria life-cycle. The antigens can be utilized to induce an immune response against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in DNA or other nucleic acid expression systems delivered as a vaccine formulation.

[object Object]

The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.

Malaria antigen screening method

The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding acircumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding aapical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.

Adenoviral vector-based malaria vaccines

Growing community of inventors

Gaithersburg, MD, United States of America

Keith Limbach